FDA Gives Clearance to a Portable Reagentless CO-oximeter
May 13, 2005 - 10:27:00 AM
|
|
|
"FDA clearance of HemoNIR(TM)LAB demonstrates the commercial capability of our near-infrared platform to monitor blood analytes. Near-infrared light offers the potential of a new standard for in-vitro and in-vivo blood testing compared to blood tests that use costly and environmentally damaging chemical reagents."
|
By NIR Diagnostics Inc.,
[RxPG] NIR Diagnostics Inc. (TSX Venture:NID), an innovative developer of handheld reagentless medical instruments
based on its proprietary near-infrared light technology, announced today that its 510(k) submission for HemoNIR(TM)LAB (for laboratory use) has been awarded clearance by the United States Food and Drug Administration (FDA).
FDA clearance allows NIR Diagnostics to market the HemoNIR(TM)LAB device and coincides with the Company's European CE Mark compliance, and the Company's most recent ISO 13485 global accreditation, a prerequisite for Canadian Health
Protection Branch (HPB) approval.
"FDA clearance of HemoNIR(TM)LAB demonstrates the commercial capability of our near-infrared platform to monitor blood analytes," said Duncan J.MacIntyre President, CEO and Executive Vice Chairman of NIR Diagnostics."Near-infrared light offers the potential of a new standard for in-vitro and in-vivo blood testing compared to blood tests that use costly and environmentally damaging chemical reagents."
HemoNIR(TM)LAB is the first medical product from NIR Diagnostics' spectroscopic technology platform to obtain FDA approval. HemoNIR(TM)LAB, which will sell for less than $5,000, offers laboratories an alternative to expensive tabletop CO-oximetry equipment that sells for as much as $45,000 and requires a painful arterial syringe blood sample drawn by a physician.
Since NIR Diagnostics submitted the HemoNIR(TM)LAB regulatory application, healthcare and medical personnel have requested that the Company also secure FDA clearance for point-of-care use. NIR Diagnostics will immediately initiate trials in Canada and the United States and file a point- of-care 510(k) submission with the FDA for HemoNIR(TM). This clearance will allow for additional use of the device on board emergency vehicles, and in military, mining and chemical plant applications.
No handheld device exists that is capable of measuring the combination of total hemoglobin (internal bleeding) and carboxyhemoglobin (carbon monoxide poisoning) for on-site
emergency use. NIR Diagnostics' technology is designed to make blood testing convenient and accessible to a broad population of potential users, just as handheld wireless devices have increased the adoption and expansion of
electronic messaging.
About HemoNIR(TM)
The HemoNIR(TM) device is the only handheld reagentless device that measures the ability of a person's blood to carry oxygen by monitoring total and non-functional hemoglobin from a drop of blood. HemoNIR(TM) specifically
measures carboxyhemoglobin, methemoglobin, and total hemoglobin in whole blood without the use of expensive and environmentally dangerous chemical reagents.
On the basis of receiving FDA clearance the Company is now in discussions with potential partners to license HemoNIR(TM) and intends to seek corporate alliances with global device companies that are capable of working with NIR
Diagnostics to bring new technology such as CardioNIR(TM) (cholesterol) and GlucoNIR(TM) (glucose) to market.
Advertise in this space for $10 per month.
Contact us today.
|
 |
Related Latest Research News
|
|
Subscribe to Latest Research Newsletter
|
|
|
|
Additional information about the news article
|
About NIR Diagnostics
NIR Diagnostics is a Canadian leader in the development of near-infrared spectroscopic medical diagnostics. The Company has an extensive portfolio of optical, electronic and algorithm related patents in the field of in-vitro and
in-vivo blood analysis.The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information:
Duncan MacIntyre, President & CEO, NIR
Diagnostics Inc., (905) 854-5727, (905) 854-5729 Fax, E-mail:
[email protected],
Internet: www.nirdiagnostics.com;
Jason Hogan,
Ross Marshall, Investor Relations, (416) 815-0700 ext. 238, (416) 815-0080
Fax, E-mail: [email protected],
Internet: www.equicomgroup.com;
To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
